Expanding Immune Intelligence with the Human Adpatome
Decoding the adaptive immune repertoire to improve health
Founded in 2009 at the HudsonAlpha Institute for Biotechnology, iRepertoire pioneered the commercialization of NGS based immune repertoire sequencing of T and B Cells, the biological frontline defense from disease and infections.
The AIRR (Adaptive Immune Receptor Repertoire) is a critical biomarker for understanding both individual historical exposure to infections and vaccines as well as the onset of autoimmune diseases and cancer. As part of the emerging multi-omics landscape, the AIRR is essential for development of a wide range of novel therapeutics including cell therapies, antibody drug conjugates, and mRNA vaccines. The AIRR also holds the potential to be leveraged as a universal indicator of health.
iRepertoire’s services are uniquely positioned to capture all seven TCR and BCR chains for a comprehensive picture of the immune system status. This allows for detailed treatment response tracking and improved patient outcomes.
At iRepertoire, scientific collaboration, curiosity, and innovation drive us. Our close-knit team fosters a creative, hands-on culture that supports both scientific breakthroughs and meaningful partnerships.
Meet the Pioneers in immune adaptome sequencing
Jian Han, M.D., Ph.D.
Founder and Chief Scientific Officer
Dr. Jian Han is a molecular diagnostics pioneer with over 30 years of experience and multiple successful biotech ventures, including Geneco, Diatherix, and iRepertoire. He holds an MD from ShuZhou Medical College and a PhD in clinical molecular genetics from UAB, and currently serves as an adjunct faculty member at HudsonAlpha Institute
Miranda Steele, Ph.D.
COO and VP of R&D
Dr. Miranda Steele leads operations and R&D at iRepertoire, co-developing key technologies like iPair and RepSeq+. She holds a PhD focused on X-ray protein structure and has authored patents in single-cell analysis, antigen-specific antibody detection, and multiplex amplification.
Dan Snyder
Head of Commercial Development
Dan Snyder is a seasoned commercial executive with over 25 years of experience scaling life science companies, including serving as CEO of MolecularMD until its acquisition by ICON plc. He holds a BA from the University of Virginia and an MBA from William and Mary.
Jonathan Doose, M.S.
Exec Director of Business Development
Jonathan Doose is a business development leader with a strong background in protein biochemistry and neuroscience, specializing in scalable sales strategies across biotech sectors. He holds both B.S. and M.S. degrees from the University of California, Riverside.
Wenjing Pan, Ph.D.
Director of Research & Development
Dr. Wenjing Pan has over 15 years of experience in molecular biology and immunology, leading the development of advanced immune repertoire sequencing technologies. He earned his PhD in Molecular Biology from the University of Alabama and previously served as a Senior Scientist at HudsonAlpha.
Kellye Kirkbride, Ph.D.
Quality Assurance Manager
Dr. Kellye Kirkbride leads the Quality Assurance program at iRepertoire, overseeing a customized Quality Management System and ensuring compliance, data integrity, and continuous improvement. She holds a Ph.D. from Duke University and brings extensive experience in cancer research, drug development, diagnostics, and next-generation sequencing across both industry and academic settings.
Mary Eisenhower
Computational Manager
Mary Eisenhower has 10 years of experience at iRepertoire where she works as both the Data Protection Officer and Systems Administrator; she has developed key software such as the iPair Analyzer. She earned a Bachelor of Electrical Engineering from the University of Alabama where she was also a member of the Engineering Honor Society.
Michael Lotze, M.D.
Chairman, Scientific Advisory Board
Dr. Michael Lotze is a leading immunotherapy expert and co-inventor of several patents in cancer immunology, with leadership roles at Nurix, Iovance, and GSK. He has held prominent academic and research positions at the University of Pittsburgh Medical Center.
The AIRR as the next frontier in biomarker development
Partnerships that drive breakthrough discoveries
